More hope comes almost every month now from reports of new approaches to treating cancer that show real promise. To me, one of the most intriguing comes from Dr. Merrill Garnett, a laboratory researcher at the Long Island High Technology Incubator in Stony Brook. Merrill has developed a group of products that use what he defines as a “second genetic code,” which bears a bit of explaining.
There’s no debate that we all have a first code of DNA containing genetic information that makes us the individuals we are and gets passed from one generation to the next. But why, Garnett asks, does a living creature’s genetic code remain unchanged when it dies? What must be missing is a second code for rapid energy storage and energy retrieval that allows us to be alive. Merrill feels this second code must exist as an electronic circuit that stores the electrical charge in DNA. Perhaps the second code is contained in “junk DNA”—the 85 percent of DNA considered extraneous to the “first” genetic code.
Merrill’s products are metal-organic compounds—liquid crystals that revive the second genetic code in animals sick with cancer. Because these crystals have the same electronic frequencies as DNA, they do to primitive cancer cells what the second genetic code should have done in the first place: destroy the cells’ membranes with one-quarter-volt electron flows.
In this country, Merrill’s products are at the investigative stage, but in other countries, they have gained registration status. I’m open to all new ideas about cancer, and so have already administered these products to many cancer patients who had not responded to other therapies. I’m excited by some of the results I’ve witnessed, and even more impressed by the absence of side effects. As a result, I’m working closely with Merrill’s company to develop an animal-specific product for veterinary medicine that already has a name: Poly-Vet. Being open to such new approaches is more than helpful in the treatment of cancer—it’s essential.